Abbott Laboratories

ABT rose 2.3% to $103.06 today, reaching intraday highs of $104.16 (up 3.4%), driven by a confluence of positive catalysts. Q2 revenue of $12.59 billion surged 13% year-over-year, prompting management to raise full-year guidance and easing growth concerns. Critically, a long-standing legal overhang has lifted—a shareholder lawsuit stemming from the 2022 infant formula recall was recently dismissed, removing years of regulatory uncertainty that had weighed on the stock. With legal risks diminished, analysts have responded with upgrades: Wells Fargo raised its price target to $112, while JPMorgan and TD Cowen maintained buy ratings; some analysts suggest the stock is undervalued by over 30% with upside potential exceeding 35%. However, Q2 earnings paint a more complex picture: EPS fell 47.5% to $0.53 year-over-year and net profit declined 47.8%, signaling that profit growth lags revenue expansion. Current valuation at PE 33.23 remains elevated relative to historical levels, warranting investor caution.

Abbott closed down 0.42% to $100.146, pressured by profit-taking and profit quality concerns. Q2 operating revenue of $12.593 billion rose 13.02% year-over-year, beating expectations, but profitability deteriorated—EPS fell 47.52% to $0.53 and net profit dropped 47.84%, eroding earnings quality and sparking selling. The stock rallied to $101.74 intraday before retreating, mirroring profit-taking after the initial upside reaction. Wall Street remains constructive: Wells Fargo raised its target to $112, implying 11.8% upside, while JPMorgan and TD Cowen maintain buy ratings, with fading legal headwinds providing support. Year-to-date, ABT is down 18.87% and trades 26.72% below its 52-week high, though above its MA20. The stock's P/E sits at 32.5x.

ABT rose 0.9% to $100.57 today, primarily boosted by better-than-expected Q2 results and raised full-year guidance. Operating revenue for the quarter reached $12.593B, up 13.02% year-over-year, though gains were offset by a 47.52% year-over-year decline in EPS to $0.53 due to one-time charges. Analyst sentiment turned positive following the results, with Wells Fargo raising its price target to $112 and both TD Cowen and Jefferies maintaining Buy ratings. Legal headwinds are also fading, with markets now viewing the stock as potentially undervalued by approximately 32%. Nevertheless, ABT remains 26.85% below its 52-week high of $137.49 and is down 19.02% year-to-date, with a PE of 32.43 that may represent a valuation ceiling for near-term appreciation.

Abbott declined 1.96% to $99.67 as the stock gradually weakened through the trading day. Pre-market trading (09:29 ET) held near $101, but the stock peaked intraday at $101.765 (10:24 ET) and subsequently deteriorated to close below $100 with a modest post-market recovery. The pullback primarily reflects profit-taking following recent rallies driven by positive catalysts: the company completed its TECTONIC IVL integration and raised guidance, prompting Wells Fargo to increase its price target to $112 and analysts to maintain buy ratings. However, Q2 earnings reveal concerning profitability deterioration—EPS crashed 47.52% to $0.53 and net profit fell 47.84% year-over-year, despite revenue growth of 13.02%, as net margin compressed from 9.65% in Q1 to 7.37%. On valuation, Abbott has retreated 27.51% from its 52-week high of $137.49 and is down 19.74% year-to-date. But earnings deterioration and recent cyber-incident disclosure add to valuation headwinds.

ABT rose roughly 1% during regular trading today, driven by Q2 results that beat expectations and prompted a full-year EPS guidance raise. Quarterly revenue grew 13% year-over-year to $12.59 billion, though EPS declined 47.52% to $0.53, but management's guidance lift signaled positive momentum. After a slight pre-market dip, regular session rallied, peaking at $102.44 at 1:51 PM ET with gains around 0.97%, while post-market extended strength to $101.73. Wells Fargo raised price target to $112, while Raymond James and TD Cowen maintained 'Buy' ratings, with institutional support underwriting the move. On valuation, ABT has rebounded about 24% from May lows, but remains down 18% year-to-date and 26% below its $137.49 52-week high.